126 related articles for article (PubMed ID: 7685420)
1. Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer.
Sadasivan R; Morgan R; Jennings S; Austenfeld M; Van Veldhuizen P; Stephens R; Noble M
J Urol; 1993 Jul; 150(1):126-31. PubMed ID: 7685420
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of her-2/neu in human prostate cancer and benign hyperplasia.
Gu K; Mes-Masson AM; Gauthier J; Saad F
Cancer Lett; 1996 Feb; 99(2):185-9. PubMed ID: 8616823
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of HER-2/neu expression in prostatic adenocarcinoma: a requested for a standardized, organ specific methodology.
Sanchez KM; Sweeney CJ; Mass R; Koch MO; Eckert GJ; Geary WA; Baldridge LA; Zhang S; Eble JN; Cheng L
Cancer; 2002 Oct; 95(8):1650-5. PubMed ID: 12365012
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma.
Ross JS; Sheehan CE; Hayner-Buchan AM; Ambros RA; Kallakury BV; Kaufman RP; Fisher HA; Rifkin MD; Muraca PJ
Cancer; 1997 Jun; 79(11):2162-70. PubMed ID: 9179063
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of HER-2/neu in patients with prostatic adenocarcinoma.
Zahir ST; Tafti HF; Rahmani K
Asian Pac J Cancer Prev; 2014; 15(15):6425-8. PubMed ID: 25124637
[TBL] [Abstract][Full Text] [Related]
6. Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization.
Liu HL; Gandour-Edwards R; Lara PN; de Vere White R; LaSalle JM
Cancer J; 2001; 7(5):395-403. PubMed ID: 11693898
[TBL] [Abstract][Full Text] [Related]
7. Expression of c-erb B-2/neu proto-oncogene in human prostatic cancer tissues and cell lines.
Zhau HE; Wan DS; Zhou J; Miller GJ; von Eschenbach AC
Mol Carcinog; 1992; 5(4):320-7. PubMed ID: 1353965
[TBL] [Abstract][Full Text] [Related]
8. Differential immunoreactivity of her-2/neu oncoprotein in prostatic tissues.
Ibrahim GK; MacDonald JA; Kerns BJ; Ibrahim SN; Humphrey PA; Robertson CN
Surg Oncol; 1992 Apr; 1(2):151-5. PubMed ID: 1285216
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastasic prostate cancer.
Morote J; de Torres I; Caceres C; Vallejo C; Schwartz S; Reventos J
Int J Cancer; 1999 Aug; 84(4):421-5. PubMed ID: 10404097
[TBL] [Abstract][Full Text] [Related]
10. Contribution of HER-2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis.
Ross JS; Nazeer T; Church K; Amato C; Figge H; Rifkin MD; Fisher HA
Cancer; 1993 Nov; 72(10):3020-8. PubMed ID: 8106140
[TBL] [Abstract][Full Text] [Related]
11. HER-2/neu: a differentiation marker in adenocarcinoma of the esophagus.
Sauter ER; Keller SM; Erner S; Goldberg M
Cancer Lett; 1993 Nov; 75(1):41-4. PubMed ID: 7904538
[TBL] [Abstract][Full Text] [Related]
12. Expression of Her-2/neu oncogene protein product and epidermal growth factor receptors in surgical specimens of human breast cancers.
Moe RE; Moe KS; Porter P; Gown AM; Ellis G; Tapper D
Am J Surg; 1991 May; 161(5):580-3. PubMed ID: 1674411
[TBL] [Abstract][Full Text] [Related]
13. Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas.
Kallakury BV; Sheehan CE; Ambros RA; Fisher HA; Kaufman RP; Muraca PJ; Ross JS
J Clin Oncol; 1998 Apr; 16(4):1302-9. PubMed ID: 9552030
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease.
Berchuck A; Rodriguez G; Kinney RB; Soper JT; Dodge RK; Clarke-Pearson DL; Bast RC
Am J Obstet Gynecol; 1991 Jan; 164(1 Pt 1):15-21. PubMed ID: 1670908
[TBL] [Abstract][Full Text] [Related]
15. Cell proliferation rate by MIB-1 immunohistochemistry predicts postradiation recurrence in prostatic adenocarcinomas.
Scalzo DA; Kallakury BV; Gaddipati RV; Sheehan CE; Keys HM; Savage D; Ross JS
Am J Clin Pathol; 1998 Feb; 109(2):163-8. PubMed ID: 9583887
[TBL] [Abstract][Full Text] [Related]
16. Correlation between immunohistochemical patterns and serum levels of PSA and PSAP in prostatic pathology: evaluation of 198 prostatic fine needle biopsies.
Vitali A; Ardoino S; Durante P; Ferro MA; Li Causi F; Parodi C; Sanguineti G; Gaffuri M; Paerachino M; Salvadori RP
Anticancer Res; 1994; 14(4A):1503-7. PubMed ID: 7526771
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer.
Rubin SC; Finstad CL; Federici MG; Scheiner L; Lloyd KO; Hoskins WJ
Cancer; 1994 Mar; 73(5):1456-9. PubMed ID: 7906607
[TBL] [Abstract][Full Text] [Related]
18. [Expression of the cerbB-2 (HER-2/neu) oncoprotein in prostatic adenocarcinoma].
San Miguel Fraile P; Dos Santos JE; Pélaez Boismorand E; Ortiz Rey JA; Iglesias Rodríguez B; Cambronero Santos J; Fajardo Seijo JL; Rodríguez Costas JM; Fernández Regueiro M
Actas Urol Esp; 2005 Jan; 29(1):64-9. PubMed ID: 15786765
[TBL] [Abstract][Full Text] [Related]
19. Quantitation of HER-2/neu oncoprotein overexpression in invasive breast cancer by image analysis: a study comparing fresh and paraffin-embedded material.
van Diest PJ; Baak JP; Chin D; Theeuwes JW; Bacus SS
Anal Cell Pathol; 1991 Jul; 3(4):195-202. PubMed ID: 1679345
[TBL] [Abstract][Full Text] [Related]
20. Her-2/neu oncogene expression in Puerto Rican females with breast cancer.
Peredo R; Sastre G; Serrano J; Hunter Mellado R
Cell Mol Biol (Noisy-le-grand); 2001 Sep; 47(6):1025-32. PubMed ID: 11785652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
